MGMT and glioblastoma: Unfortunately, the nomograms proposed by Gorlia et al. for GBM patients who received the standard treatment (population 2 and population 3 of the EORTC trial) were not evaluated in the study by Parks et al. However, our study confirmed the appropriateness of Gorlia et al. findings as we also identified MGMT methylation status, performance status, age and extent of surgery in the nomogram for the population of GBM patients assigned to standard treatment.